| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ligand, Has Profound Effects on Immune Responses In Vivo1
,,,
* Research Service, Veterans Affairs San Diego Healthcare System,
Biomedical Sciences Graduate Program, and Departments of
Cellular and Molecular Medicine and
Medicine, University of California, San Diego, CA 92161
Peroxisome proliferator-activated receptors (PPARs) are
ligand-activated transcription factors with diverse actions. PPAR
and PPAR
are expressed in different lymphocyte subpopulations.
Recently, we have observed that PPAR ligands elicit augmented IL-4
expression in cultures of mitogen-activated splenocytes. The following
studies were undertaken to characterize the in vivo effects of
WY14,643, a PPAR ligand. Our studies demonstrate that oral
administration of WY14,643 markedly reduces splenocyte number in
immunized and nonimmunized C57BL/6 mice. Mice fed WY14,643 display
impaired IgG responses to myelin oligodendrocyte glycoprotein peptide
35–55 (pMOG35–55), following immunization with
pMOG35–55/CFA. Following in vitro restimulation with
pMOG35–55, splenocytes harvested from WY14,643-fed mice
demonstrate impaired production of IFN-, IL-6, and TNF- despite
similar proliferative responses. We also demonstrate higher expression
of PPAR in B than T cells. Finally, to obtain an understanding of
the cause of splenocyte depletion with fibrate therapy, we studied the
effect of WY14,643 on apoptosis of activated splenocytes. WY14,643 in
vitro induces apoptosis in lymphocytes and this effect appears to occur
in a PPAR-independent manner. Thus WY14,643, a fibrate, is a
profound immunosuppressive agent.
This article has been cited by other articles:
|
|
 |
|
  A. R. Gocke, R. Z. Hussain, Y. Yang, H. Peng, J. Weiner, L.-H. Ben, P. D. Drew, O. Stuve, A. E. Lovett-Racke, and M. K. Racke Transcriptional Modulation of the Immune Response by Peroxisome Proliferator-Activated Receptor-{alpha} Agonists in Autoimmune Disease J. Immunol., April 1, 2009; 182(7): 4479 - 4487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. H. Smeets, H. M. de Vogel-van den Bosch, P. H. M. Willemsen, A. P. Stassen, T. Ayoubi, G. J. van der Vusse, and M. van Bilsen Transcriptomic analysis of PPAR{alpha}-dependent alterations during cardiac hypertrophy Physiol Genomics, December 12, 2008; 36(1): 15 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Fang, L. Zhang, Y. Feng, Y. Zhao, and J. Dai Immunotoxic Effects of Perfluorononanoic Acid on BALB/c Mice Toxicol. Sci., October 1, 2008; 105(2): 312 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Peden-Adams, J. M. Keller, J. G. EuDaly, J. Berger, G. S. Gilkeson, and D. E. Keil Suppression of Humoral Immunity in Mice following Exposure to Perfluorooctane Sulfonate Toxicol. Sci., July 1, 2008; 104(1): 144 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Keil, T. Mehlmann, L. Butterworth, and M. M. Peden-Adams Gestational Exposure to Perfluorooctane Sulfonate Suppresses Immune Function in B6C3F1 Mice Toxicol. Sci., May 1, 2008; 103(1): 77 - 85. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Dubrac, P. Stoitzner, D. Pirkebner, A. Elentner, K. Schoonjans, J. Auwerx, S. Saeland, P. Hengster, P. Fritsch, N. Romani, et al. Peroxisome Proliferator-Activated Receptor-{alpha} Activation Inhibits Langerhans Cell Function J. Immunol., April 1, 2007; 178(7): 4362 - 4372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Yessoufou, A. Hichami, P. Besnard, K. Moutairou, and N. A. Khan Peroxisome Proliferator-Activated Receptor {alpha} Deficiency Increases the Risk of Maternal Abortion and Neonatal Mortality in Murine Pregnancy with or without Diabetes Mellitus: Modulation of T Cell Differentiation Endocrinology, September 1, 2006; 147(9): 4410 - 4418. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K. Racke, A. R. Gocke, M. Muir, A. Diab, P. D. Drew, and A. E. Lovett-Racke Nuclear Receptors and Autoimmune Disease: The Potential of PPAR Agonists to Treat Multiple Sclerosis J. Nutr., March 1, 2006; 136(3): 700 - 703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Liu, C.-C. Chien, M. Burne-Taney, R. R. Molls, L. C. Racusen, R. B. Colvin, and H. Rabb A Pathophysiologic Role for T Lymphocytes in Murine Acute Cisplatin Nephrotoxicity J. Am. Soc. Nephrol., March 1, 2006; 17(3): 765 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. E. Lovett-Racke, R. Z. Hussain, S. Northrop, J. Choy, A. Rocchini, L. Matthes, J. A. Chavis, A. Diab, P. D. Drew, and M. K. Racke Peroxisome Proliferator-Activated Receptor {alpha} Agonists as Therapy for Autoimmune Disease J. Immunol., May 1, 2004; 172(9): 5790 - 5798. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Srinivasan, M. E. Hatley, K. B. Reilly, E. C. Danziger, and C. C. Hedrick Modulation of PPAR{alpha} Expression and Inflammatory Interleukin-6 Production by Chronic Glucose Increases Monocyte/Endothelial Adhesion Arterioscler. Thromb. Vasc. Biol., May 1, 2004; 24(5): 851 - 857. [Abstract] [Full Text]
|
|
|
|
|
|
J. Bassaganya-Riera, R. M. Pogranichniy, S. C. Jobgen, P. G. Halbur, K.-J. Yoon, M. O'Shea, I. Mohede, and R. Hontecillas Conjugated Linoleic Acid Ameliorates Viral Infectivity in a Pig Model of Virally Induced Immunosuppression J. Nutr., October 1, 2003; 133(10): 3204 - 3214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Jones, X. Ding, T. Y. Zhang, and R. A. Daynes Peroxisome Proliferator-Activated Receptor {alpha} Negatively Regulates T-bet Transcription Through Suppression of p38 Mitogen-Activated Protein Kinase Activation J. Immunol., July 1, 2003; 171(1): 196 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Angeli, H. Hammad, B. Staels, M. Capron, B. N. Lambrecht, and F. Trottein Peroxisome Proliferator-Activated Receptor {gamma} Inhibits the Migration of Dendritic Cells: Consequences for the Immune Response J. Immunol., May 15, 2003; 170(10): 5295 - 5301. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
